# Asymmetric Syntheses of (+)-Diltiazem Hydrochloride

**Keith G. Watson,*[a] Yik M. Fung,[a] Matthew Gredley,[a] Graham J. Bird,[a] W. Roy Jackson,*[b] Helen Gountzos,[b] and Barry R. Matthews[b]**

[a] *Research Group, I.C.I. Australia Operations Pty. Ltd, Newsom Street, Ascot Vale, Victoria 3032, Australia*
[b] *Department of Chemistry, Monash University, Clayton, Victoria 3168, Australia*

Efficient enantioselective syntheses of the important cardiac drug (+)-*cis*-(2*S*,3*S*)-diltiazem from (*E*)-methyl 4-methoxyphenylpropenoate *via* either the (2*R*,3*S*)- or (2*S*,3*R*)-enantiomers of *threo*-methyl 3-(4-methoxyphenyl)-2,3-dihydroxypropanoate are described.

(+)-(2*S*,3*S*)-*cis*-Diltiazem hydrochloride (**6**) is a potent vasodilating agent discovered by Tanabe Seiyaku Co. Ltd. that possesses calcium channel blocking activity.[1] Several synthetic approaches have been described[2] of which many are in the patent literature.[3] All but one appear to involve a classical resolution. The one asymmetric synthesis was patented by another Japanese pharmaceutical company.[4] It involves an asymmetric Sharpless epoxidation but suffers from having a large number of steps.

We now report efficient syntheses of (+)-diltiazem (**6**) from (*E*)-methyl 4-methoxypropenoate *via* either of the enantiomers of *threo*-methyl 3-(4-methoxyphenyl)-2,3-dihydroxypropanoate (**2**). Both of these enantiomers are available in excellent chemical yield (>95%) and high optical purity (≥88%) by reaction of the (*E*)-propenoate (**1**) with *N*-methylmorpholine *N*-oxide using catalytic amounts of osmium tetroxide and either dihydroquinine or dihydroquinidine acetates as ligands.[5] Recrystallisation of this material from toluene led to a further increase in enantiomeric purity and material with an enantiomeric excess (e.e.) of ≥97% was obtained in *ca.* 80% yield. The catalytic method used the same ligands as those described by Sharpless for the asymmetric dihydroxylation using stoicheiometric amounts of osmium tetroxide and a chiral ligand.[6] Subsequently, Sharpless described a catalytic method similar to ours with a further modification which generally gives 1,2-diols at a faster rate and in even higher enantiomeric excess.[7]

The enantiomeric diols (**2**) are also available by an alternative synthetic route[8] from (*R*)- or (*S*)-4-methoxybenzaldehyde cyanohydrins which are readily available in high optical purity by hydrocyanation of 4-methoxybenzaldehyde in the presence of Inoue catalyst.[9]

The synthetic strategy involves conversion of the enantiomers of (**2**) into the *threo*-(2*S*,3*S*)-thioether (**5**) which is an intermediate in the Tanabe synthesis of (+)-diltiazem.[10] Conversion of the (2*R*,3*S*)-diol (**2**) involves reactions which lead to *retention* of configuration at both C-2 and C-3. The method by which this has been achieved is outlined in Scheme




**Scheme 1.** *Reagents and conditions*: i, *N*-methylmorpholine *N*-oxide, $OsO_4$–dihydroquinine acetate, 80%; ii, $MeC(OMe)_3$, *p*-$MeC_6H_4SO_3H$, *ca.* 100%; iii, $Me_3SiCl$, $Et_3\overset{+}{N}HCl^-$ (trace), *ca.* 100%; iv, *o*-$H_2NC_6H_4S^-K^+$ in dimethylformamide (DMF), *ca.* 100%; v, reactions as in Tanabe synthesis,[10] 81%.




**Scheme 2.** *Reagents and conditions*: i, tricsyl (Trc) chloride–pyridine, 95%; ii, NaH–THF, 97%; iii, *o*-$O_2NC_6H_4SH$, $NaHCO_3$, EtOH, 60%; iv, $H_2$, Pd–C, EtOAc; NaOH, EtOH/$H_2O$, 95%; v, reactions as in Tanabe synthesis,[10] 81%.

1. The cyclic orthoacetate (**3**) was prepared by the general procedure of Dansette and Jerina.[11] It was shown to react with trimethylsilyl chloride in the presence of a catalytic amount of triethylammonium chloride with both high regio- and stereoselectivity to give the chloroacetate (**4**). Reaction of the chloroacetate (**4**) with potassium *o*-aminobenzenethiolate gave the *threo*-(2*S*,3*S*)-thioether (**5**) which was converted into (+)-diltiazem by the Tanabe route.[10] Use of the *threo*-diol (**2**) with e.e. ≥97% gave (+)-diltiazem hydrochloride with $[\alpha]_D^{21}$ 104.5° (*c* 2.50, $CHCl_3$), {authentic sample, $[\alpha]_D^{21}$ 103.7° (*c* 2.53, $CHCl_3$)}. The overall yield from the propenoate was 65%.

Conversion of the (2*S*,3*R*)-enantiomer of the *threo*-diol (**2**) into the (2*S*,3*S*)-thioether (**5**) involves reactions which lead to the *inversion* of configuration at both chiral centres. This was achieved by reaction of a sample of the diol (**2**), rich in the (2*S*,3*R*)-enantiomer (e.e. 85%), with 2,4,6-trichlorobenzenesulphonyl chloride (tricsyl chloride)[12] (see Scheme 2). This bulky reagent reacted regiospecifically at the C-2-hydroxy group of (**2**) to give the tricsylester (**7**). Treatment of (**7**) with sodium hydride in tetrahydrofuran (THF) gave the *cis*-epoxide (**8**), $[\alpha]_D^{18}$ +5.3° (*c* 0.826, $CHCl_3$). Spectral data for this compound and for a sample of racemic material prepared by the same method were in good agreement with those previously reported for a sample of the racemic epoxide (**8**) prepared by another route.[13] The *cis*-epoxide (**8**) has been previously shown to undergo highly stereoselective *syn*-ring opening in a tin-catalysed reaction with 2-nitrobenzenethiol leading to the *erythro*-diastereoisomer of (**9**).[2,13] However, reaction of (**8**) with 2-nitrobenzenethiol in the presence of a catalytic amount of sodium hydrogen carbonate and in the absence of tin salts was found to give exclusively the *threo*-thioether (**9**) with $[\alpha]_D^{20}$ +123.5° (*c* 0.56, $CHCl_3$). The same enantiomer has recently been prepared by an efficient resolution procedure with $[\alpha]_D^{25}$ +121° (*c* 1, $CHCl_3$).[14] The enantiomeric purity of our sample of this compound was confirmed as being ≥97% by $^1H$ NMR chiral shift experiments carried out on a sample of the acetate of (**9**). Thus enantiomeric enrichment of the material had occurred during the purification sequence. A sample of (**9**) was hydrogenated and hydrolysed to give the key intermediate, the hydroxy-amino acid (**5**) which had $[\alpha]_D$ +332° (*c* 0.634, EtOH) suggesting an e.e. value of 96% by comparison with the published literature value, $[\alpha]_D$ +346°, EtOH.[10]

Thus highly stereoselective routes to (+)-diltiazem hydrochloride (**1**) are available *via* either of the enantiomers of the *threo*-diol (**2**). Overall yields of enantiomerically pure (+)-diltiazem from 4-methoxyphenylpropenoate are 65% for the orthoester route (Scheme 1) and 43% for the epoxide route (Scheme 2). These yields have not been optimised for either route.

We thank the Australian Department of Education for a postgraduate award (to B. R. M.).

*Received, 10th April 1990; Com. 0/01623C*

## References

1 T. Nagao, M. Sato, H. Nakajima, and A. Kiyomoto, *Chem. Pharm. Bull.*, 1973, **21**, 92.
2 T. Hashiyama, H. Inoue, M. Takeda, K. Aoe, and K. Kotera, *J. Chem. Soc., Perkin Trans. 1*, 1985, 421, and references therein.
3 Tanabe Seiyaku Co. Ltd, Jpn. Pat., J.P. 59 20, 273 (1984); *Chem. Abstr.*, 1984, **101**, 38486e.
4 Shionogi and Co. Ltd, Ger. Pat., DE 341 5035 (1984); *Chem. Abs.*, 1984, **102**, 185114f.
5 M. Gredley, I.C.I. Australia Operations Pty. Ltd, PCT Int. Appl. WO 89 02428; *Chem. Abstr.*, 1989, **111**, 173782v.
6 S. G. Hentges and K. B. Sharpless, *J. Am. Chem. Soc.*, 1980, **102**, 4263.
7 E. N. Jacobsen, I. Marko, W. S. Mungall, G. Schroder, and K. B. Sharpless, *J. Am. Chem. Soc.*, 1988, **110**, 1968; J. S. M. Wai, I. Marko, J. S. Svendsen, M. G. Finn, E. N. Jacobsen, and K. B. Sharpless, *ibid.*, 1989, **111**, 1123.
8 B. R. Matthews, H. Gountzos, W. R. Jackson, and K. G. Watson, *Tetrahedron Lett.*, 1989, 5157.
9 W. R. Jackson, G. S. Jayatilake, B. R. Matthews, and C. Wilshire, *Aust. J. Chem.*, 1988, **41**, 203.
10 Tanabe Seiyaku Co. Ltd, US Pat., USP 4 416819 (1983); *Chem. Abstr.*, 1983, **100**, 85 733x.
11 P. Dansette and D. M. Jerina, *J. Am. Chem. Soc.*, 1974, **96**, 1224.
12 R. D. Guthrie and S. Thang, *Aust. J. Chem.*, 1987, **40**, 2133.
13 T. Hashiyama, H. Inoue, N. Konda, and M. Takeda, *J. Chem. Soc., Perkin Trans. 1*, 1984, 1725.
14 M. Senuma, M. Shibazaki, S. Nishimoto, K. Shibata, K. Okamura, and T. Date, *Chem. Pharm. Bull.*, 1989, **37**, 3204.